Edit

Voluntis

https://www.voluntis.com/

Last activity: 03.10.2023

Active

Categories: CareHardwareHealthTechMedTechMobilePersonalRecommendationsSoftwareTechnologyWeb

Voluntis innovates healthcare solutions by embedding connectivity in therapeutics and medical intelligence in software.

Mentions

Total raised: $35.99M

Investors 3

Date	Name	Website
-	LBO France	lbofrance....
-	Karista Ve...	karista.vc
-	Debiopharm	debiopharm...

Funding Rounds 2

Date	Series	Amount	Investors
23.11.2020	-	$6.99M	-
28.04.2014	Series D	$29M	-

Mentions in press and media 23

Date	Title	Description
03.10.2023	Is Patient Relationship Management the Future of Healthcare Information Technology?	Key Takeaways: Voluntis is a healthcare software company specialized in Patient Relationship Management (PRM). Founded in 2001, Voluntis aims to improve healthcare outcomes and efficiency through advanced information technologies. With over...
18.10.2021	Voluntis : Voluntis announces the success of the Tender Offer initiated by the company Aptar allowing the implementation of mandatory squeeze-out	Cambridge (USA), Paris (France), October 18, 2021 - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960 - "the Company"), a leader in the field of digital therapeutics, announces the successful completion of the Si...
18.10.2021	Voluntis : announces the success of the Tender Offer initiated by the company Aptar allowing the implementation of mandatory squeeze-out	home News Voluntis announces the success of the Tender Offer initiated by the company Aptar allowing the implementation of mandatory squeeze-out Voluntis announces the success of the Tender Offer initiated by the company Aptar allowing the ...
24.09.2021	Voluntis : Voluntis announces its results for the first half of 2021	Decline in commercial invoicing to € 1.5 million and IFRS revenue to € 1.3 million in H1 2021 Significant increase in deferred revenues to € 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic...
24.09.2021	Voluntis : announces its results for the first half of 2021	home News Voluntis announces its results for the first half of 2021 Voluntis announces its results for the first half of 2021 Finance Institutional 24 September 2021 Cambridge (USA), Paris (France) - Decline in commercial invoicing to € 1.5...
03.09.2021	Voluntis : announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of 8.70 per share	home News Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of €8.70 per share Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price o...
03.09.2021	Voluntis : Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of EUR 8.70 per share	Cambridge (USA), Paris (France), September 2, 2021 11pm CET – Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gesti...
24.07.2021	Voluntis : Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of EUR 8.70 ...	Cambridge (USA), Paris (France), July 23, 2021, 11pm CET – Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion,...
24.07.2021	Voluntis : announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of 8.70 per share	home News Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of €8.70 per share Voluntis announces the execution o...
07.06.2021	VOLUNTIS Voluntis : Voluntis receives FDA 510(k) clearance for a new version of Insulia supporting an expanded range of basal insulins	Insulia, a digital therapeutic, is now cleared by the FDA for use by people with type 2 diabetes, using a wide range of basal insulin analogues, including all approved insulin glargines Expanded range of supported insulins also integrated i...
12.05.2021	VOLUNTIS Voluntis : Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence	New regulatory approval in the European Union for an enhanced version of Oleena extending its patient decision support algorithms New version now authorized for marketing in the United States and the European Union 13th regulatory clearance...
23.11.2020	Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing	CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in the field of digital therapeutics, announces today the completion of a capital increase without preferential...
21.01.2020	Digital health, digital therapeutics, digital medicines – what’s in a name?	To differentiate themselves from the health and wellness pack, digital therapeutics have attempted to back claims that they can prevent or treat certain conditions with clinical evidence. There’s still a lot of wiggle room in that definitio...
13.08.2019	Digital Therapeutics Hot Summer With Major IPOs and First Oncology App
07.08.2019	Voluntis gets FDA nod for its Oleena cancer management product	“Beyond monitoring their symptoms, we believe that empowering patients via the digital delivery of real-time and personalized therapeutic interventions offers the opportunity for significant clinical and economic outcomes,” said Voluntis CE...
21.12.2018	За параноиками реально следят, но не так тщательно, как за сахаром в крови. Цифровая терапевтика. Часть вторая	Цифровая таблетка от компании Proteus WSJ 0 Обсудить 388 просмотров Продолжение. Часть первая. Представьте, что у вашего собеседника параноидальная шизофрения, и он говорит вам, что за ним следят, с помощью миниатюрного передатчика в его же...
06.12.2016	Basal insulin dosage management tool for Type 2 diabetes gets greenlight from FDA	Voluntis CEO and Founder Pierre Leurent explained how the product works in a phone interview. Physicians prescribe the app to patients. They create accounts for patients through a portal. An activation code is generated that allows patients...
28.04.2014	Voluntis raises $29M to bring diabetes app to US	Voluntis's app (not shown here) was one of the first to work with Sanofi's IBGStar connected glucometer. Paris, France-based Voluntis, a developer of companion apps for medical devices, has raised $29 million in its fourth round of funding....
28.04.2014	Voluntis Raises $29M	PARIS, FRANCE, Voluntis, a pioneer in therapeutic companion software, has closed a major Series D financing. >> Click here for more funding data on Voluntis >> To export Voluntis funding data to PDF and Excel, click here ...
28.04.2014	Voluntis Closes €20.75M Series D Financing	Voluntis, a Paris, France-based therapeutic companion software, closed a €20.75m ($29m) Series D financing. The round was co-led by Bpifrance and Innovation Capital, with participation from Vesalius Biocapital, Qualcomm, through its venture...
-	Digital health, digital therapeutics, digital medicines – what’s in a name?	As the digital health industry gains ground, companies have bandied about all sorts of terminology. Some sell digital medicines. Others sell digital therapeutics. One company that went public last year describes itself as an “applied health...
-	Basal insulin dosage management tool for Type 2 diabetes gets greenlight from FDA	Voluntis Insulia app A connected therapeutics company has received 510(k) clearance from the U.S. Food and Drug Administration for a physician-driven dosage management platform for basal insulin geared for Type 2 diabetes patients. Voluntis...
-	Voluntis gets FDA nod for its Oleena cancer management product	French digital health company Voluntis recently received clearance by the FDA for its cancer management platform. Dubbed Oleena, the company’s software acts as an aid for cancer patients by helping users self-manage their disease symptoms a...

Voluntis

Investors 3

Funding Rounds 2

Mentions in press and media 23

Reviews 0